FDA — authorised 21 June 2005
- Application: ANDA077349
- Marketing authorisation holder: PERRIGO R AND D
- Status: supplemented
FDA authorised 200mg on 21 June 2005
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 21 June 2005; FDA authorised it on 10 December 2010; FDA authorised it on 7 October 2016.
PERRIGO R AND D holds the US marketing authorisation.